Role of adjuvant therapy in intermediate-risk cervical cancer patients - Subanalyses of the SCCAN study.

ABSTRACT:

Objective

The "intermediate-risk" (IR) group of early-stage cervical cancer patients is characterized by negative pelvic lymph nodes and a combination of tumor-related prognostic risk factors such as tumor size ≥2 cm, lymphovascular space invasion (LVSI), and deep stromal invasion. However, the role of adjuvant treatment in these patients remains controversial. We investigated whether adjuvant (chemo)radiation is associated with a survival benefit after radical surgery in patients with IR cervical cancer.

Methods

We analyzed data from patients with IR cervical cancer (tumor size 2-4 cm plus LVSI OR tumor size >4 cm; N0; no parametrial invasion; clear surgical margins) who underwent primary curative-intent surgery between 2007 and 2016 and were retrospectively registered in t

SUBMITTER: Cibula D 

PROVIDER: S-EPMC10281542 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature